G1 Therapeutics, Inc. (GTHX) Tops Q4 EPS by 7c ; Offers Guidance

G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $14.87 million versus the consensus estimate of $13.08 million.

GUIDANCE:

G1 Therapeutics, Inc. sees FY2024 revenue of $60-70 million, versus the consensus of $66.25 million.

For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Logistic Properties of the Americas (LPA) Reports Q2 results
• ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c